OROS hydromorphone HCI (slow release)

DRUG3 trials

Sponsors

Alza Corporation, DE, USA

Conditions

Analgesics, OpioidOsteoarthritis, HipOsteoarthritis, KneePain

Phase 1

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

CompletedNCT00410878

Alza Corporation, DE, USAAnalgesics, Opioid, Pain

End: 1999-08-31Updated: 2017-02-17

Phase 3

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

CompletedNCT00411164

Alza Corporation, DE, USAOsteoarthritis, Hip, Osteoarthritis, Knee

Start: 2003-11-30End: 2005-05-31Updated: 2013-07-08

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

CompletedNCT00410787

Alza Corporation, DE, USAAnalgesics, Opioid, Pain

End: 2002-04-30Updated: 2010-04-27